Value Bridge — COOPERMAN BARNABAS MEDICAL CENTER
Current $-46M → Target $-23M (+$23.7M)
🛡️ Public data only — no PHI permitted on this instance.
← DashboardPRFProfileMEMIC MemoBRGBridgeCIComp IntelSCNScenariosAIMLDCFDCFLBOLBOFIN3-StmtMKTMarketDENDenialRETReturnsLVRLeversWFLWaterfallPLYPlaybookTRDTrendsPREDPredictedMEM2Memo
$-46.2M
Current EBITDA
$-22.5M
Target EBITDA
+$23.7M
Total Uplift
7
Value Levers
EBITDA Bridge — 7 Lever Model
Each lever shows gross impact, probability of achievement, and probability-weighted value.
Denial Rate Reduction
$0.0M
AR Acceleration
$0.0M
Coding Accuracy Uplift
$5.4M
Payer Mix Optimization
$12.9M
Cost to Collect Reduction
$4.3M
Clean Claim Improvement
$3.2M
Volume & Rate Growth
$21.4M
What This Means
The 7-lever model projects a 0% EBITDA uplift from $-46M to $-23M. The highest-impact lever is Volume & Rate Growth at $8.6M probability-weighted.
IC talking point: "We see $24M in annual EBITDA improvement, primarily from volume & rate growth. At an 11x multiple, this represents $261M in equity value creation."